Fibrin clot strength is associated with increased risk of major adverse cardiac events after TAVR

Cardiovascular Risk and Diseases

Improved prediction and risk stratification of major adverse cardiovascular events using an explainable machine learning approach combining plasma biomarkers and traditional risk factors

Cardiovasc Diabetol

Zhang XR, Zhong WF, Liu RY, Huang JL, Fu JX, Gao J, Zhang PD, Liu D, Li ZH, He Y, Zhou H, Li Z

doi: 10.1186/s12933-025-02711-x

Cardiovascular Risk and Diseases

Risk acceleration by gout on major adverse cardiovascular events and all-cause death in patients with diabetes and chronic kidney disease

Diabetes Obes Metab

Lee DY, Moon JS, Jung I, Chung SM, Park SY, Yu JH, Seo JA, Han KD, Kim NH

doi: 10.1111/dom.16165

ESC 2025

Cardiovascular Risk and Diseases

Older age and low fitness levels are associated with arrhythmias that increase future cardiovascular risk

Cardiovascular Risk and Diseases

Effect of sotagliflozin on major adverse cardiovascular events: a prespecified secondary analysis of the SCORED randomised trial

Lancet Diabetes Endocrinol

Aggarwal R, Bhatt DL, Szarek M, Cannon CP, Leiter LA, Inzucchi SE, Lopes RD, McGuire DK, Lewis JB, Riddle MC, Davies MJ, Banks P, Carroll AK, Scirica BM, Ray KK, Kosiborod MN, Cherney DZI, Udell JA, Verma S, Mason RP, Pitt B, Steg PG

doi: 10.1016/S2213-8587(24)00362-0

Heart, Artery and Coronary Diseases

Redefining the risk of major arrhythmic events in non-ischaemic cardiomyopathy: insights from the DERIVATE-NICM study

Eur Heart J Cardiovasc Imaging

Guaricci AI, Carrabba N, Romano SM, Chiostri M, Fusini L, Baggiano A, Mushtaq S, Volpe A, Abete R, Aquaro GD, Barison A, Basile P, Bogaert J, Calo' L, Camastra G, Carigi S, Casavecchia G, Censi S, Cicala G, Ciccone MM, De Cecco CN, De Lazzari M, Di Giovine G, Dobrovie M, Focardi M, Gaibazzi N, Gismondi A, Gravina M, Guglielmo M, Lanzillo C, Lombardi M, Lorenzoni V, Lozano-Torres J, Margonato D, Martini C, Marzo F, Masci PG, Masi A, Moro C, Muscogiuri G, Nese A, Palumbo A, Pavon AG, Pedrotti P, Perazzolo Marra M, Pradella S, Presicci C, Rabbat MG, Raineri C, Rodriguez-Palomares JF, Casas G, Rodenas-Alesina E, Giustiniani A, Sbarbati S, Schoepf UJ, Squeri A, Sverzellati N, Symons R, Tat E, Timpani M, Todiere G, Valentini A, Varga-Szemes A, Schwitter J, Pontone G

doi: 10.1093/ehjci/jeaf198

Cardiovascular Risk and Diseases

Low serum 1,5-anhydroglucitol is associated with increased risk of all-cause and cardiovascular mortality in type 2 diabetes: A real-world cohort study

Diabetes Obes Metab

Ni J, Chen L, Su H, Cai J, Wang C, Lu W, Wang Y, Lu J, Xia T, Zhou J

doi: 10.1111/dom.70214

Cardiac Arrest or Death

Prearrest Vital Sign Abnormalities are Associated with Adverse Outcomes in Pediatric ICU Cardiac Arrest: A Get with the Guidelines-Resuscitation Analysis

Resuscitation

Mehta SD, Gathers CA, Shepard LN, Putt M, Yehya N, Graham K, Morgan RW, Sutton RM, American Heart Association’s Get With The Guidelines®-Resuscitation Investigators

doi: 10.1016/j.resuscitation.2025.110846

Cardiac Arrest or Death

Association of Non-Cardiac Depolarization-Blocking Drugs with First-Registered Heart Rhythm and Survival in Out-of-Hospital Cardiac Arrest

Resuscitation

Hindborg M, Coronel R, Arulmurugananthavadivel A, Parveen S, Yonis H, Andersen MP, Sørensen KK, Christensen HC, Torp-Pedersen C, Gislason G, Eroglu TE

doi: 10.1016/j.resuscitation.2025.110903

Heart, Artery and Coronary DiseasesTherapy and Intervention

Cardiac Biomarkers in Patients with Asymptomatic Severe Aortic Stenosis: Analysis from the EARLY TAVR Trial

Circulation

Lindman BR, Pibarot P, Schwartz A, Oldemeyer JB, Su YR, Goel K, Cohen DJ, Fearon WF, Babaliaros V, Daniels D, Chhatriwalla A, Suradi HS, Shah P, Szerlip M, Mack MJ, Dahle T, O'Neill WW, Davidson CJ, Makkar R, Sheth T, Depta J, DeVries JT, Southard J, Pop A, Sorajja P, Hahn RT, Zhao Y, Leon MB, Généreux P, EARLY TAVR Trial Executive Committee and Study Investigators

doi: 10.1161/CIRCULATIONAHA.125.074425

Related content

Improved prediction and risk stratification of major adverse cardiovascular events using an explainable machine learning approach combining plasma biomarkers and traditional risk factors

Risk acceleration by gout on major adverse cardiovascular events and all-cause death in patients with diabetes and chronic kidney disease

Older age and low fitness levels are associated with arrhythmias that increase future cardiovascular risk

Effect of sotagliflozin on major adverse cardiovascular events: a prespecified secondary analysis of the SCORED randomised trial

Redefining the risk of major arrhythmic events in non-ischaemic cardiomyopathy: insights from the DERIVATE-NICM study

Low serum 1,5-anhydroglucitol is associated with increased risk of all-cause and cardiovascular mortality in type 2 diabetes: A real-world cohort study

Prearrest Vital Sign Abnormalities are Associated with Adverse Outcomes in Pediatric ICU Cardiac Arrest: A Get with the Guidelines-Resuscitation Analysis

Association of Non-Cardiac Depolarization-Blocking Drugs with First-Registered Heart Rhythm and Survival in Out-of-Hospital Cardiac Arrest

Cardiac Biomarkers in Patients with Asymptomatic Severe Aortic Stenosis: Analysis from the EARLY TAVR Trial